-
Je něco špatně v tomto záznamu ?
Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome
M. Hofer, Z. Hoferová, M. Falk,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
19-09212S
Grantová Agentura České Republiky
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- akutní radiační syndrom krev farmakoterapie etiologie metabolismus MeSH
- cyklooxygenasa 1 metabolismus MeSH
- cyklooxygenasa 2 metabolismus MeSH
- hematopoéza účinky léků MeSH
- inhibitory cyklooxygenasy 2 farmakologie terapeutické užití MeSH
- lidé MeSH
- metabolické sítě a dráhy účinky léků MeSH
- modely nemocí na zvířatech MeSH
- prostaglandiny biosyntéza farmakologie MeSH
- radioprotektivní látky farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both prostaglandins and COX inhibitors were reported to act positively in radiation-exposed mammalian organisms at various pre- and post-irradiation therapeutical settings. Experimental efforts were targeted at finding pharmacological procedures leading to optimization of therapeutical outcomes by minimizing undesirable side effects of the treatments. Progress in these efforts was obtained after discovery of selective inhibitors of inducible selective cyclooxygenase-2 (COX-2) inhibitors. Recent studies have been able to suggest the possibility to find combined therapeutical approaches utilizing joint administration of prostaglandins and inhibitors of their synthesis at optimized timing and dosing of the drugs which could be incorporated into the therapy of patients with acute radiation syndrome.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005720
- 003
- CZ-PrNML
- 005
- 20200518132037.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules24224019 $2 doi
- 035 __
- $a (PubMed)31698831
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hofer, Michal $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 245 10
- $a Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome / $c M. Hofer, Z. Hoferová, M. Falk,
- 520 9_
- $a Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both prostaglandins and COX inhibitors were reported to act positively in radiation-exposed mammalian organisms at various pre- and post-irradiation therapeutical settings. Experimental efforts were targeted at finding pharmacological procedures leading to optimization of therapeutical outcomes by minimizing undesirable side effects of the treatments. Progress in these efforts was obtained after discovery of selective inhibitors of inducible selective cyclooxygenase-2 (COX-2) inhibitors. Recent studies have been able to suggest the possibility to find combined therapeutical approaches utilizing joint administration of prostaglandins and inhibitors of their synthesis at optimized timing and dosing of the drugs which could be incorporated into the therapy of patients with acute radiation syndrome.
- 650 _2
- $a akutní radiační syndrom $x krev $x farmakoterapie $x etiologie $x metabolismus $7 D054508
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a cyklooxygenasa 1 $x metabolismus $7 D051545
- 650 _2
- $a cyklooxygenasa 2 $x metabolismus $7 D051546
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x farmakologie $x terapeutické užití $7 D052246
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a hematopoéza $x účinky léků $7 D006410
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metabolické sítě a dráhy $x účinky léků $7 D053858
- 650 _2
- $a prostaglandiny $x biosyntéza $x farmakologie $7 D011453
- 650 _2
- $a radioprotektivní látky $x farmakologie $x terapeutické užití $7 D011837
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hoferová, Zuzana $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 700 1_
- $a Falk, Martin $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 24, č. 22 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31698831 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200518132037 $b ABA008
- 999 __
- $a ok $b bmc $g 1524578 $s 1095776
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 22 $e 20191106 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a 19-09212S $p Grantová Agentura České Republiky
- LZP __
- $a Pubmed-20200511